Literature DB >> 10698200

Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors.

R J Bollag1, Q Zhong, P Phillips, L Min, L Zhong, R Cameron, A L Mulloy, H Rasmussen, F Qin, K H Ding, C M Isales.   

Abstract

Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide synthesized and secreted from endocrine cells in the small intestine. The role of GIP in coupling nutrient intake and insulin secretion, the incretin effect, is well known. We report that GIP receptor messenger RNA and protein are present in normal bone and osteoblast-like cell lines, and that high affinity receptors for GIP can be demonstrated by [125I]GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated increases in cellular cAMP content and intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I messenger RNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblast-like cells and that GIP modulates the function of these cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698200     DOI: 10.1210/endo.141.3.7366

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  55 in total

1.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

Review 2.  Relationships between fat and bone.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  2007-10-27       Impact factor: 4.507

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

4.  Exercise Decreases Marrow Adipose Tissue Through ß-Oxidation in Obese Running Mice.

Authors:  Maya Styner; Gabriel M Pagnotti; Cody McGrath; Xin Wu; Buer Sen; Gunes Uzer; Zhihui Xie; Xiaopeng Zong; Martin A Styner; Clinton T Rubin; Janet Rubin
Journal:  J Bone Miner Res       Date:  2017-05-04       Impact factor: 6.741

Review 5.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa.

Authors:  Monica H Wojcik; Erinne Meenaghan; Elizabeth A Lawson; Madhusmita Misra; Anne Klibanski; Karen K Miller
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

8.  Glucose-Dependent Insulinotropic Peptide Prevents Serum Deprivation-Induced Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells.

Authors:  J L Berlier; I Kharroubi; J Zhang; A Dalla Valle; S Rigutto; M Mathieu; V Gangji; J Rasschaert
Journal:  Stem Cell Rev Rep       Date:  2015-12       Impact factor: 5.739

9.  Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.

Authors:  Ke-Hong Ding; Xing-Ming Shi; Qing Zhong; Baolin Kang; Ding Xie; Wendy B Bollag; Roni J Bollag; William Hill; Walter Washington; Qing-Sheng Mi; Karl Insogna; Norman Chutkan; Mark Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

Review 10.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.